PEDIATRICS Vol. 99 No. 5 May 1997, pp. 655-659 (doi:10.1542/peds.99.5.655)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simons, F. E. R.
Right arrow Articles by Cheang, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simons, F. E. R.
Right arrow Articles by Cheang, M. S.
Related Collections
Right arrow Respiratory Tract

PEDIATRICS Vol. 99 No. 5 May 1997, pp. 655-659

Tolerance to the Bronchoprotective Effect of Salmeterol in Adolescents With Exercise-induced Asthma Using Concurrent Inhaled Glucocorticoid Treatment

Received Jul 8, 1996; accepted Aug 27, 1996.

F. Estelle R. Simons*, Thomas V. Gerstner*, and Mary S. CheangDagger

From the * Department of Pediatrics and Child Health, and the Dagger  Department of Community Health Sciences, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.

Objectives.  The long-acting beta 2-adrenergic agonist salmeterol prevents exercise-induced asthma, but tolerance may develop to its bronchoprotective effect. We wanted to ascertain if the development of tolerance could be prevented by using a low-dose treatment regimen of 50 µg once daily, instead of the usual dose of 50 µg twice daily, in adolescents receiving regular glucocorticoid inhalations.

Methods.  In a randomized, double-blind, 2x28-day crossover study, we administered salmeterol (50 µg) or placebo once daily via a metered-dose inhaler and Nebulizer Chronolog device to monitor compliance. Exercise challenge tests were performed 1 and 9 hours after salmeterol or placebo inhalation on the 1st and 28th day of each treatment period. The primary outcome variable was the maximum decrease in percent predicted FEV1 postexercise.

Results.  Fourteen subjects with a mean age of 13.1 years completed the study. The first dose of salmeterol had an excellent bronchoprotective effect against exercise-induced asthma at 1 and 9 hours. After the 28th consecutive daily dose of salmeterol, the bronchoprotective effect was significantly greater than that of placebo at 1 hour, but not at 9 hours.

Conclusions.  We conclude that a single 50-µg dose of salmeterol has an excellent protective effect against exercise-induced asthma for at least 9 hours, but that this effect may wane during regular once-daily salmeterol treatment, despite the reduced frequency of dosing and despite concomitant use of inhaled glucocorticoids.

Key words: exercise-induced asthma, salmeterol, beta 2-adrenergic agonist, inhaled glucocorticoid, beclomethasone dipropionate.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
F. M. de Benedictis, M. M. del Giudice, N. Forenza, F. Decimo, D. de Benedictis, and A. Capristo
Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children
Eur. Respir. J., August 1, 2006; 28(2): 291 - 295.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter
Meta-Analysis: Respiratory Tolerance to Regular {beta}2-Agonist Use in Patients with Asthma
Ann Intern Med, May 18, 2004; 140(10): 802 - 813.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
M J Vaquerizo, P Casan, J Castillo, M Perpina, J Sanchis, V Sobradillo, A Valencia, H Verea, J L Viejo, C Villasante, et al.
Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma
Thorax, March 1, 2003; 58(3): 204 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
B. Dahlen, P.M. O'Byrne, R.M. Watson, A. Roquet, F. Larsen, and M.D. Inman
The reproducibility and sample size requirements of exercise-induced bronchoconstriction measurements
Eur. Respir. J., April 1, 2001; 17(4): 581 - 588.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S.L. Jones, J.O. Cowan, E.M. Flannery, R.J. Hancox, G.P. Herbison, and D.R. Taylor
Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol
Eur. Respir. J., March 1, 2001; 17(3): 368 - 373.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. Jokic, V. A. Swystun, B. E. Davis, and D. W. Cockcroft
Regular Inhaled Salbutamol : Effect on Airway Responsiveness to Methacholine and Adenosine 5'-Monophosphate and Tolerance to Bronchoprotection
Chest, February 1, 2001; 119(2): 370 - 375.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
D R Taylor and R J Hancox
Interactions between corticosteroids and beta agonists
Thorax, July 1, 2000; 55(7): 595 - 602.
[Full Text]

Home page
 ANN INTERN MEDHome page
J. M. Edelman, J. A. Turpin, E. A. Bronsky, J. Grossman, J. P. Kemp, A. F. Ghannam, P. T. DeLucca, G. J. Gormley, D. S. Pearlman, and for the Exercise Study Group*
Oral Montelukast Compared with Inhaled Salmeterol To Prevent Exercise-Induced Bronchoconstriction: A Randomized, Double-Blind Trial
Ann Intern Med, January 18, 2000; 132(2): 97 - 104.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. C. AHRENS, L. HENDELES, W. R. CLARKE, R. J. DOCKHORN, M. R. HILL, L. M. VAUGHAN, C. LUX, and S.-H. HAN
Therapeutic Equivalence of Spiros Dry Powder Inhaler and Ventolin Metered Dose Inhaler . A Bioassay Using Methacholine
Am. J. Respir. Crit. Care Med., October 1, 1999; 160(4): 1238 - 1243.
[Abstract] [Full Text]

Home page
 PediatricsHome page
E. A. Bronsky, D. S. Pearlman, B. F. Pobiner, C. Scott, Y. Wang, and E. Stahl
Prevention of Exercise-induced Bronchospasm in Pediatric Asthma Patients: A Comparison of Two Salmeterol Powder Delivery Devices
Pediatrics, September 1, 1999; 104(3): 501 - 506.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
H. Milgrom and L. M. Taussig
Keeping Children With Exercise-induced Asthma Active
Pediatrics, September 1, 1999; 104 (3): e38 - e38.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. F. Lockey, L. M. DuBuske, B. Friedman, V. Petrocella, F. Cox, and K. Rickard
Nocturnal Asthma: Effect of Salmeterol on Quality of Life and Clinical Outcomes
Chest, March 1, 1999; 115(3): 666 - 673.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
I. Aziz, B. J. Lipworth, B. F. Dickey, R. Adachi, P. K. Honig, J. K. Jenkins, D. A. Stempel, E.R. McFadden, L. Strauss, J. A. Nelson, et al.
Exercise-Induced Asthma
N. Engl. J. Med., December 10, 1998; 339(24): 1783 - 1786.
[Full Text]

Home page
 NEJMHome page
J. Hansen-Flaschen and H. Schotland
New Treatments for Exercise-Induced Asthma
N. Engl. J. Med., July 16, 1998; 339(3): 192 - 193.
[Full Text]

Home page
 NEJMHome page
F. E. R. Simons and The Canadian Beclomethasone Dipropionate-Salmetero
A Comparison of Beclomethasone, Salmeterol, and Placebo in Children with Asthma
N. Engl. J. Med., December 4, 1997; 337(23): 1659 - 1665.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. F. LEMANSKE JR. and D. B. ALLEN
Choosing a Long-term Controller Medication in Childhood Asthma . The Proverbial Two-edged Sword
Am. J. Respir. Crit. Care Med., September 1, 1997; 156(3): 685 - 687.
[Full Text] [PDF]

Home page
 JWatch GeneralHome page
SALMETEROL TOLERANCE IN KIDS WITH EXERCISE-INDUCED ASTHMA
Journal Watch (General), May 13, 1997; 1997(513): 3 - 3.
[Full Text]

Home page
 PediatricsHome page
P. A. Eggleston
Are beta -Adrenergic Bronchodilators Safe?
Pediatrics, May 1, 1997; 99(5): 729 - 729.
[Full Text]